Cube Labs

Name

Cube Labs

Legal name

Cube Labs S.p.A.

Website

https://cube-labs.com

Company type

Public

Founded year

2023

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Healthcare Technology Venture Building

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Investment Advice (6282)

akta.pro primary industry

Corporate Accelerators & Startup Programs (FSANAHAD)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Life sciences venture building
• Healthcare startup incubation
• Academic research commercialization
• Biotech venture development
• Medical technology investing

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Venture Building / Equity Investments: Cube Labs creates and takes equity stakes in healthcare technology startups spun out from academic research. Returns are generated through equity appreciation, exit events (acquisitions, IPOs), and portfolio company growth.
2. Technology Licensing and Commercialization: Licensing technologies developed by portfolio companies to strategic commercial partners. Examples include Theakine IBS-C and Theakine Prost, where Adamas Biotech seeks licensing partners for distribution of registered nutraceutical products.
3. Capital Increases: Periodic capital increases on Euronext Growth Milan to fund operations and portfolio company development. Recent 2026 capital increase raised €2 million with participation from founder/CEO and institutional investors at €2.40 per share.
4. Public Grants and Subsidized Funding: Portfolio companies access non-dilutive funding through programs such as NBFC (National Biodiversity Future Center) grants: Adamas Biotech received €425,700 and DTech received €393,700 for specific R&D projects under PNRR / Next Generation EU.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cube Labs is Italy's first systematic venture builder in healthcare technology, creating and developing startups from promising academic R&D projects across Pharmaceuticals, BioTech, Nutraceuticals, R&D Tech/AI, and MedTech. The company provides pre-seed funding of up to €500,000 per startup, laboratory infrastructure, IP development, regulatory navigation, and operational support to bring academic scientific discoveries to market. It holds equity in 18 portfolio companies with 60+ patents, brings products like Theakine nutraceuticals and Neuretina MD to market, and monetizes through licensing deals and capital increases on Euronext Growth Milan.

Product overview

Cube Labs operates as Italy's first dedicated healthcare technology venture builder, creating and developing startups from promising academic R&D projects. The company provides entrepreneurial, operational, and financial support to transform pioneering science into scalable healthcare solutions. The portfolio includes 18 healthcare startups across Pharmaceuticals, BioTech, Nutraceuticals, R&D Tech/AI, and MedTech sectors, with over 60 patents secured and two products brought to market. Key portfolio companies include Adamas Biotech (nutraceuticals with Theakine® IBS-C and Theakine® Prost products), DTech (wound care technology), Biodiapers (absorbent products), Bio Aurum (medical devices including Neuretina MD), Cartilago (regenerative medicine), Lipovexa (diabetes/obesity treatments), FluoDetect (microplastic detection), Hiperforming Research (AI for healthcare), and others. The company is listed on Euronext Growth Milan, Professional Segment.

Differentiator

Problem solved

Functional benefit

Products and services

• Cube Labs Venture Building Platform End-to-end venture building service providing up to €500,000 pre-seed funding, laboratory infrastructure, IP development, regulatory navigation, and operational support to healthcare technology startups spun out of academic research.
• Theakine IBS-C Bicomponent dietary supplement formulated with patented Theaphenon E green tea extract and probiotics, marketed by portfolio company Adamas Biotech for individuals with IBS-C and intestinal health concerns.
• Theakine Prost Dietary supplement based on green tea catechins (Theaphenon E) for prostate wellness and associated disorders, marketed by portfolio company Adamas Biotech.
• Neuretina MD Innovative software medical device that receives camera input to record and analyze eye movements, evaluating test execution time and error percentage in visual character recognition for healthcare professionals to detect neurodegenerative disease markers.

Quantifiable outcome

• 18 healthcare startups launched
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature13 records

Partnerships

Ten partnerships are on record, tiered major, core and minor.

• IRCCS San RaffaelemajorStrategic or Co-development Partner · 9 October 2025Collaboration agreement signed October 2025 with IRCCS San Raffaele to promote technology transfer in life sciences. The agreement aims to accelerate the translation of research into clinical applications through joint initiatives.
• Tecnopolo RomamajorStrategic or Co-development Partner · 5 June 2025Collaboration agreement signed June 2025 with Tecnopolo Roma to promote innovation and technology transfer in life sciences. The agreement facilitates the establishment and development of new companies, startups, and spin-offs primarily in the bio-pharmaceutical and medical devices chain at the Castel Romano area, where Cube Labs already has an operational office.
• Università del SalentomajorStrategic or Co-development Partner · 10 April 2025Three-year scientific and technological collaboration agreement with the Dipartimento di Ingegneria dell'Innovazione of Università del Salento, covering joint research activities, co-funded R&D projects, training initiatives, technology transfer seminars, internship programs, and business matching activities. Students will initially intern at the Maglie office.
• National Biodiversity Future Center (NBFC)coreStrategic or Co-development Partner · 10 April 2025NBFC, Italy's first national research and innovation center dedicated to biodiversity coordinated by CNR (Consiglio Nazionale delle Ricerche), awarded grants to portfolio companies Adamas Biotech (€425,700) and DTech (€393,700) for innovative R&D projects under PNRR / Next Generation EU.
• FTherapeuticscoreTechnology or Integration · 12 April 2024Collaboration agreement with FTherapeutics (Spanish cluster) and its companies Synthelia Organics (medicinal chemistry) and Nostrum Biodiscovery (AI-powered drug discovery) to advance early-stage drug discovery and development projects. FTherapeutics brings expertise from multinational pharma experience (Ely Lilly, GSK) in computational chemistry, organic chemistry, biochemistry, and medicinal chemistry.
• Marzotto Venture AcceleratorminorStrategic or Co-development Partner · 1 April 2024Collaboration with Marzotto Venture Accelerator as co-developers of the Master's program in Life Science Venturing Innovation with Università Campus Bio-Medico di Roma.
• Università Campus Bio-Medico di RomamajorStrategic or Co-development Partner · 1 October 2023Partnership with Università Campus Bio-Medico di Roma as co-founders of the Second-level University Master's program in Life Science Venturing Innovation. Cube Labs oversees the Venture Builder module, providing field experience and best practices. The program targets managers and experts in Life Sciences to develop specialized managerial and entrepreneurial skills.
• Modi Science Foundation / Modi Global EnterprisescoreStrategic or Co-development Partner · 1 September 2023Strategic cooperation agreement signed September 2023 with Modi Science Foundation for scientific, technological, and commercial collaboration in life science and biotech innovation in India. The partnership aims to establish a future joint venture for developing the Indian market. Modi Global Enterprises is a major Indian industrial conglomerate with $3 billion in revenue. The alliance was announced at the first Prix Galien India Awards in New Delhi.
• Sicam S.r.l.minorStrategic or Co-development Partner · 31 May 2023Development agreement with Sicam S.r.l. for prototyping Biodiapers' absorbent core for infant, feminine, and adult incontinence products. Sicam, with over 50 years of experience in technical textiles, developed a biodegradable and compostable 'pre-formed functional core' using no chemical binders, achieving performance comparable or superior to conventional technologies.
• Istituto Nazionale Biostrutture e Biosistemi (INBB)coreStrategic or Co-development PartnerExclusive strategic partnership with INBB, Italy's main interuniversity consortium in life sciences, comprising 24 public universities and 700+ researchers. This partnership is the primary source of academic research projects for Cube Labs' venture building activities, providing continuous pipeline of spin-off opportunities.

Scale indicators21 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Roivant Sciences: Roivant is a public healthcare "vants" platform that creates, funds, and develops multiple therapeutic subsidiary companies — the closest direct analog to Cube Labs' venture-builder model, including a similar public-listing structure and diversified biopharma portfolio approach.
• PureTech Health: PureTech is a public clinical-stage biotherapeutics company that invents, develops, and operates a portfolio of differentiated therapeutics and technology platforms — directly comparable to Cube Labs in founding, incubating, and listing multiple healthcare subsidiaries.
• BridgeBio Pharma: BridgeBio is a public commercial-stage biopharmaceutical company that operates a portfolio model focused on genetic disease and oncology, building multiple subsidiaries around academic research — analogous to Cube Labs' academic-pipeline approach.
• BioGeneration Ventures: BioGeneration Ventures is a European early-stage venture capital firm dedicated to life sciences, building companies from academic discoveries in biotech, medtech, and pharma — closely comparable in deal sourcing and stage of investment.

Regional players

• Indaco Venture Partners: Indaco is Italy's largest life-science-dedicated venture capital firm, actively investing in early-stage Italian biotech, medtech, and digital health — overlapping with Cube Labs' Italian academic-to-market investment thesis.
• Principia SGR: Principia SGR is an Italian asset management company running a dedicated healthcare/biotech venture capital fund (PHI Fund) investing in early-stage life-science companies — a domestic Italian peer in the same biotech/medtech investment space.

Broad incumbents

• Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds across biotech and medtech, with a broader AUM and global reach — comparable in portfolio-construction approach but at materially greater scale.
• Sofinnova Partners: Sofinnova is a leading European venture capital firm specializing in life sciences, particularly therapeutics and medical devices — comparable as a European life-sciences VC but operating from a broader fund-management platform rather than an operating venture-builder.
• Bayer CoLaborator / Leaps by Bayer: Leaps by Bayer and Bayer CoLaborator are Bayer's venture-creation arms investing in and partnering with breakthrough life-science and healthcare startups — analogous strategic-venture-builder activity but at the scale of a global life-sciences major.

Peers

• JLABS (Johnson & Johnson Innovation):

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries14 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cube Labs